Amicus Therapeutics Sees 41.7% Surprise, Q4 Sales Estimated at $179.9M
Amicus Therapeutics has missed earnings in three of the last four quarters, delivering a negative surprise of 20.21%, though it beat estimates by 41.67% in the recent quarter. Analysts forecast fourth-quarter sales of $179.9 million and EPS of $0.13, while BioMarin’s acquisition and strong Galafold uptake may bolster growth.
1. Earnings Performance
Amicus has missed earnings estimates in three of the last four quarters, with an aggregate negative surprise of 20.21%. However, the company outperformed in the most recent quarter, beating EPS forecasts by 41.67%.
2. Q4 Forecasts
Analysts project fourth-quarter sales of $179.9 million and EPS of $0.13, reflecting expected growth from Galafold revenue and ongoing clinical developments. The zero percent Earnings ESP indicates limited upside in current consensus estimates per the predictive model.
3. BioMarin Acquisition and Galafold Uptake
Amicus’s pending acquisition by BioMarin will integrate Galafold into a larger immunology and rare disease portfolio, potentially accelerating commercialization. Continued strong Galafold uptake is expected to support revenue stability and contribute to post-deal synergies.